SCHEMBL6490620

SCHEMBL6490620

Cc1ccc(S(=O)(=O)N2CCN(C(CSCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)c3ccccc3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
MAOA P21397 1/20 0.47
PKM P14618 1/20 0.46
LMNA P02545 6/20 0.46
TACR1 P25103 2/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
GAA P10253 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
STAT1 P42224 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478373 0.88 PKM (0.51) ALDH1A1MAOAPKMLMNAGAA
SCHEMBL6479618 0.76 PKM (0.56) ALDH1A1MAOAPKMLMNAGAA
SCHEMBL6480929 0.75 PKM (0.62) ALDH1A1MAOAPKMLMNAGAA
SCHEMBL6491049 0.75 PKM (0.62) ALDH1A1MAOAPKMLMNAGAA
SCHEMBL6490508 0.75 PKM (0.59) ALDH1A1MAOAPKMLMNAGAA
SCHEMBL31350802 0.70 MAOA (0.76) ALDH1A1MAOAPKMTDP1CYP3A4
SCHEMBL31646967 0.69 ALDH1A1 (0.70) ALDH1A1MAOAPKMLMNAMAPK1
SCHEMBL11628895 0.67 GAA (0.86) ALDH1A1PKMLMNAGAASMN1; SMN2
SCHEMBL3927929 0.65 GAA (0.56) ALDH1A1MAOAPKMLMNATDP1
SCHEMBL587788 0.65 CYP3A4 (0.68) ALDH1A1MAOAPKMLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6916797-B2 α-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2005-07-12 US disclosed
US-20030220323-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2003-11-27 US disclosed
EP-1242399-A1 $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS UCB S.A. (BE) 2002-09-25 EP disclosed
WO-2001046167-A1 α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS UCB, S.A. (BE) 2001-06-28 WO disclosed
EP-1110958-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists UCB, S.A. (BE) 2001-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220323-A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists TACR1, TACR2, NPSR1 ALDH1A1 1102/4885MAOA 836/4885PKM 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.